Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Clin Chem. 2020 Nov 1;66(11):1367-1368. doi: 10.1093/clinchem/hvaa222.
In the United States, response to the COVID-19 coronavirus pandemic has been hampered by inadequate testing resources for the causative virus SARS-CoV-2. In the early part of the pandemic, United States laboratories were initially heavily regulated and slow to provide testing. As the pandemic has progressed, the supply chain for instruments and reagents has been inconsistent and has revealed weaknesses in traditional sophisticated infectious disease testing. Testing capabilities of clinical laboratories could be substantially improved by assays that are more simplified and do not require multiple consumable reagents for extraction, purification, amplification and detection. One such technology with the potential to require minimal reagents is matrix-assisted laser desorption/ionization combined with mass spectrometry (MALDI-MS). Recently, Nachtigall and colleagues reported the development of a MALDI-MS method for the diagnosis of SARS-CoV-2 infection (1).
在美国，由于 SARS-CoV-2 病毒的检测资源不足，应对 COVID-19 冠状病毒大流行的工作受到了阻碍。在大流行的早期，美国的实验室最初受到严格监管，并且检测速度缓慢。随着大流行的进展，仪器和试剂的供应链一直不稳定，暴露出传统复杂传染病检测的弱点。通过更简化且不需要用于提取、纯化、扩增和检测的多种消耗性试剂的检测方法，可以大大提高临床实验室的检测能力。其中一种具有潜在可能性的技术是基质辅助激光解吸/电离结合质谱法（MALDI-MS）。最近，Nachtigall 及其同事报道了一种用于 SARS-CoV-2 感染诊断的 MALDI-MS 方法的开发（1）。
